Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Haldol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Haloperidol 10 mg Tablets (Cord Laboratories) |
| 2 | ACTIVE_COMPARATOR | Haldol 10 mg Tablets (McNeil Pharmaceuticals) |
| Name | Type | Description |
|---|---|---|
| Haloperidol 10 mg Tablets (Cord Laboratories) | DRUG | - |
| Haldol 10 mg Tablets (McNeil Pharmaceuticals) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Haldol is a small molecule drug developed by Novartis AG (ticker NVS) for psychosis in the psychiatry therapeutic area. It is also known as Haldol 10 mg Tablets (McNeil Pharmaceuticals). It is investigational and has been studied in a Phase 1 clinical trial.
Haldol is used for psychosis. It is being developed by Novartis AG (ticker NVS) for this indication. The drug is investigational and has been evaluated in a Phase 1 clinical trial.
Haldol is developed by Novartis AG, which trades under the ticker NVS. The drug is also known as Haldol 10 mg Tablets (McNeil Pharmaceuticals).
Haldol is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed.
Haldol has been studied in one completed Phase 1 trial, NCT00946491, titled 'To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers.' The trial enrolled 30 healthy male volunteers aged 35 years and older and was active-controlled.